Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37582952

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Nat Med
Publication date
2023 Sep
First author
Lesokhin AM

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Lesokhin AM
      type
      Author
    2. name
      Tomasson MH
      type
      Author
    3. name
      Arnulf B
      type
      Author
    4. name
      Bahlis NJ
      type
      Author
    5. name
      Miles Prince H
      type
      Author
    6. name
      Niesvizky R
      type
      Author
    7. name
      Rodrίguez-Otero P
      type
      Author
    8. name
      Martinez-Lopez J
      type
      Author
    9. name
      Koehne G
      type
      Author
    10. name
      Touzeau C
      type
      Author
    11. name
      Jethava Y
      type
      Author
    12. name
      Quach H
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Lesokhin AM
      type
      Author
    2. name
      Tomasson MH
      type
      Author
    3. name
      Arnulf B
      type
      Author
    4. name
      Bahlis NJ
      type
      Author
    5. name
      Miles Prince H
      type
      Author
    6. name
      Niesvizky R
      type
      Author
    7. name
      Rodrίguez-Otero P
      type
      Author
    8. name
      Martinez-Lopez J
      type
      Author
    9. name
      Koehne G
      type
      Author
    10. name
      Touzeau C
      type
      Author
    11. name
      Jethava Y
      type
      Author
    12. name
      Quach H
      type
      Author
    bibliography ids
    1. nci-bib-99552d38d1e2c4f5d229b9d6
    book metadata
    content sha256
    52180a19d1692e4f0347a2a36b7ed0b39d3f2fd07f0bbabaee391604c7935abf
    document type
    citation
    dois
    1. 10.1038/s41591-023-02528-9
    electronic publication date
    display
    2023 Aug 15
    precision
    day
    year
    2023
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:37582952
    immutable id
    pubmed:37582952@52180a19d1692e4f0347a2a36b7ed0b39d3f2fd07f0bbabaee391604c7935abf
    journal
    abbreviation
    Nat Med
    issn electronic
    1546-170X
    issn print
    1078-8956
    issue
    9
    name
    Nature medicine
    nlm unique id
    9502015
    pages
    2259-2267
    volume
    29
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      37582952
      provenance
      batch id
      5329a5d0877ee70ecd11
      provider
      NCBI PubMed ESummary
      record sha256
      5c7e751a84c13aa027c492cf86c5fdb110cd475ee189cd8fb5954a4f5285d653
      response sha256
      bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
      retrieved at
      2026-09-09T23:48:15.763286+00:00
      publication date
      display
      2023 Sep
      precision
      month
      year
      2023
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      3. Research Support, N.I.H., Extramural
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/37582952/
      title
      Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.

      Preserved source evidence · Not medical advice